Medicare To Limit Coverage Of Contentious And Costly Alzheimer’s Drug
The Centers for Medicare and Medicaid Services says it will pay for Adulhelm, Biogen's $28,000-a-year treatment for Alzheimer's disease, but initially plans to restrict coverage to patients with early-stage symptoms who enroll in a clinical trial supported by the National Institutes of Health. The move reflects ongoing concerns over safety and effectiveness of the drug.